← Back
Immix Biopharma
IMMX · listed on Nasdaq · worth $868.49 million
$8.13
−3.76% on Oct 30
Two insider buys in the last year, $10K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
56.2M shares
79% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders bought Immix Biopharma stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
CFO
Gabriel S. Morris
Bought $5.1K on Dec 10, 2025 — 770 shares at $6.58, 0.3% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
CEO and Chairman
Ilya M. Rachman
Bought $5K on Dec 10, 2025 — 746 shares at $6.67, 0.1% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of Immix Biopharma, newest first.
All reports
Every insider trade and SEC report we hold for Immix Biopharma.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Jun 20, 2025BoughtIlya M. RachmanJun 20, 2025 · Traded Jun 18, 2025 · CEO and Chairman+0.2%2,178 @ $2.30$5K
1 more with Pro →Analysts, earnings and news
Analysts' price target
$23.78 average
8 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 4 quarters above
Q2 '26−$0.18 a share−$0.00
Q1 '26−$0.18 a share+$0.03
Q4 '25−$0.28 a share−$0.12
Q3 '25−$0.24 a share−$0.05